Related Experiment Video

Updated: May 28, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib-induced asthenia: from molecular basis to clinical relief

Luis M Antón Aparicio1, Enrique Grande Pulido, Guadalupe Aparicio Gallego

  • 1Clinical Oncology Department, A Coruña University Hospital, A Coruña, Spain. Luis.M.Anton.Aparicio@sergas.es

Cancer Biology & Therapy
|November 3, 2011
PubMed

Insights

Sunitinib, a cancer drug, can cause persistent fatigue, known as asthenia-fatigue syndrome (AFS). This study explores the unknown molecular reasons behind sunitinib-induced AFS, aiming to improve cancer patient care.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Asthenia-fatigue syndrome (AFS) is persistent tiredness impacting cancer patients' quality of life.
  • Sunitinib, a tyrosine kinase inhibitor, is frequently associated with AFS, but its mechanisms are poorly understood.
  • AFS can occur even without other identifiable adverse events during sunitinib treatment.

Purpose of the Study:

  • To investigate the elusive molecular mechanisms underlying sunitinib-induced AFS in cancer patients.
  • To hypothesize potential pathways involved in sunitinib's induction of AFS.
  • To contribute to a better understanding of sunitinib's toxicity and optimize its clinical application.

Main Methods:

  • Review of clinical observations and existing metabolic and pharmacological data.
  • Analysis of sunitinib's known off-target tyrosine kinase interactions.
  • Hypothesis generation based on molecular mechanisms of kinase inhibition.

Main Results:

  • Sunitinib inhibits multiple tyrosine kinases by blocking ATP-binding sites.
  • The broad kinase inhibition profile of sunitinib may contribute to its toxicity, including AFS.
  • Hypotheses regarding molecular mechanisms of sunitinib-induced AFS were formulated.

Conclusions:

  • The precise molecular mechanisms driving sunitinib-induced AFS remain to be fully elucidated.
  • Understanding these mechanisms is crucial for optimizing sunitinib's use in cancer therapy.
  • Further research into sunitinib's molecular actions could mitigate AFS and improve patient outcomes.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...